Method of preventing or reducing the progression of prostate cancer
AssigneeNymox Corporation
InventorPaul Averback
Life of this patent
Estimating the term…
Abstract
The embodiments include methods of preventing or reducing the progression of prostate cancer in mammals susceptible to developing prostate cancer, and to methods of reducing the incidence of clinically detected prostate cancer, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.
Claims16
A method of reducing the incidence of clinically detected prostate cancer in a mammal comprising administering to the mammal a therapeutically effective amount of an isolated peptide comprising the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu, wherein the method reduces the incidence of clinically detected prostate cancer by an amount greater than about 15%, when compared to mammals receiving a placebo.
A method of reducing the progression of prostate cancer in a mammal susceptible to developing prostate cancer as determined by one or more prostate cancer screening techniques, comprising administering to the mammal a therapeutically effective amount of an isolated peptide comprising the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu, wherein the method reduces the progression of prostate cancer to an amount within the range of from about 0% to less than about 5%.
Dependencies are inferred from the claim text.